Altria Group and Cronos Group are two names making headlines in the medical marijuana industry. Cronos announced on 7 December that they have agreed to a $2.4 billion (Canadian dollars) investment from Altria Group. Shareholders approved of this agreement on 21 February of this year. This deal has a few implications for the budding field of medical cannabis, but before we get into that, we need to look at who these groups are and why they may—or may not be—major players.
According to the Cronos website, they “are a geographically diversified and vertically integrated cannabis group” from Canada that “operates within Health Canada’s Access to Cannabis for Medical Purposes Regulations and distributes globally.” That is a wordy way to say that they grow cannabis and create marijuana products within Canada’s legal framework.
Altria, on the other hand, is a United States tobacco corporation. They are a massive producer of tobacco products—one of the largest in the world. Most people know the name Philip Morris. That was Altria before the rebranding that took place in 2003.
Now that we have taken a brief look at the players, what are the implications of this investment?
Right off the bat, the knee-jerk reaction is to be upset that a cannabis group sold out to a tobacco company. Altria is not just any tobacco company either. Like others, they have a history that is peppered with shady activity.
In 2006 Altria was found guilty of racketeering and civil fraud. While they got off the chopping block—which should not come as a surprise given that Philip Morris spends millions on lobbying—this did nothing to garner faith in their brand. People view them as an evil corporation. That’s because they are an evil corporation. For decades now they have manufactured, supplied, and marketed cigarettes. There is no question that tobacco cigarettes are harmful, to say the least. However, the investment into Cronos could see some benefits for both parties.
Due to the investment, Cronos will have access to more funds for development, marketing, and research. The investment also comes with brand recognition that looks strong to potential investors. Altria’s stocks do well enough, and other investors will see the investment as a power move.
We reached out to both parties, but both declined to offer quotes on the investment. Regardless, both sides seem to be excited.
Mike Gorenstein, CEO of Cronos Group, said that Altria’s “expertise and complementary capabilities will better position Cronos Group to support our efforts in cannabinoid innovation, as well as the creation of differentiated products and brands across medical and recreational channels and throughout our global network.” It seems that the plan is in some way to use the funds and brand recognition to develop new cannabis products.
It is clear that the products will be focused not only on recreational use—as Philip Morris has been known to focus on, the recreational use of tobacco—but also on medical marijuana products. This is a massive upside to the whole deal.
Seeing new, innovative medical cannabis products means that more ways to help patients in pain will be sought. Just about any investment into the safe, natural, and smart relief of pain, illness, and suffering is a good investment. This is because companies should be considering that people are people, not products. Bottom lines will still be met if the focus switches from pure profit to compassion. Companies can grow souls—they just need to work harder at it.
Overall, the investment from Altria Group into Cronos Group looks to be interesting, if not great. The possibilities are there for amazing work to be done, but that will fall into the hands of those at the top of both companies.
As long as they each strive to pursue avenues of genuine progress there will be no issue. That is a tall order for Altria Group. But Cronos is still a relatively new company. Their brand is smaller than other cannabis companies, but their potential is unlimited. The ball is in their court at this point.
No matter the initial implications of this investment, time will shed some light on the outcome. Let’s hope it’s a bright light.
Have you ever consumed cannabis and gotten a little too high for your liking? Or have you ever needed to calm down a friend who consumed too much weed for their tolerance level? If so, we’ve got you covered. Although an overdose (taking more than what is medically recommended) of delta-9 tetrahydrocannabinol (THC) is not…
Cannabis tinctures are relatively new on the scene compared to the long, thousands-year-old history of the cannabis plant itself. It was first recognized for its medicinal use in European medicine in 1839, and by 1851, medicinal cannabis tinctures had made their way into a drug almanac known as the United States Pharmacopeia. Despite prohibition throughout…
When Piper Lindeen’s son Zach began showing medical issues at just three years old, no one suspected a rare, severe form of epilepsy. Doctors initially didn’t recognize his symptoms as seizures. Eventually, they diagnosed Zach with epilepsy—but by then, his condition had worsened from a few seizures a week to several each day. As it…
Over the years, Hollywood has had a mixed relationship with cannabis. Portrayals have run the gamut from weed as the devil’s lettuce, able to ruin your life and destroy your mind after just a single puff, to a beneficial, life-giving MacGuffin. Because American audiences have such wide-ranging attitudes towards weed— according to the Pew Research…
You may think that when someone has a medical cannabis card, they are able to use cannabis however their medical practitioner sees fit. However, this is not always the case! Depending on someone’s employment and place of work, they may not be able to use cannabis, even if they were to obtain a medical cannabis…
Sign up for our newsletter
Get your medical marijuana card today
Sign up in under 5 minutes
Start By Selecting Your State
